Abstract:There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development. Dysbiosis, a deleterious change in gut microbiota composition, leads to altered intestinal permeability, associated with obesity and Type 2 diabetes. Many factors affect the homeostasis of gut microbiota, including diet, genetics, circadian rhythms, medication, probiotics, and antibiotics. In addition, bariatric surgery induces changes in gut microbiota that contributes to the metabolic benefits observed post-surgery. Current obesity management strategies encompass dietary interventions, exercise, pharmacotherapy, and bariatric surgery, with emerging treatments including microbiota-altering approaches showing promising efficacy. While pharmacotherapy has demonstrated significant advancements in recent years, bariatric surgery remains one of the most effective treatments for sustainable weight loss. However, access to this is generally limited to those living with severe obesity. This underscores the need for non-surgical interventions, particularly for adolescents and mildly obese patients. In this comprehensive review, we assess longitudinal alterations in gut microbiota composition and functionality resulting from the two currently most effective anti-obesity treatments: pharmacotherapy and bariatric surgery. Additionally, we highlight the functions of gut microbiota, focusing on specific bacteria, their metabolites, and strategies for modulating gut microbiota to prevent and treat obesity. This review aims to provide insights into the evolving landscape of obesity management and the potential of microbiota-based approaches in addressing this pressing global health challenge.

The complex link between the gut microbiome and obesity-associated metabolic disorders: Mechanisms and therapeutic opportunities

The links between gut microbiota and obesity and obesity related diseases

The microbiome's influence on obesity: mechanisms and therapeutic potential

The Gut Microbial Regulation of Epigenetic Modification from a Metabolic Perspective

Exploring a novel therapeutic strategy: the interplay between gut microbiota and high-fat diet in the pathogenesis of metabolic disorders

The critical role of gut microbiota in obesity

Gut microbiota and its metabolites: Bridge of dietary nutrients and obesity-related diseases

Gut Microbiota and Adipose Tissue Microenvironment Interactions in Obesity

The role of the gut microbiome and its metabolites in metabolic diseases

Diet-gut microbiota-epigenetics in metabolic diseases: From mechanisms to therapeutics

High Fat Diet, Gut Microbiota and Metabolic Health

The Epigenetic Connection Between the Gut Microbiome in Obesity and Diabetes

Is the Gut Microbiota a New Factor Contributing to Obesity and Its Metabolic Disorders?

Gut microbial metabolite short-chain fatty acids and obesity

Gut mycobiome in metabolic diseases: Mechanisms and clinical implication

The Role of Gut Microbiota Modulation Strategies in Obesity: The Applications and Mechanisms

Role of oral and gut microbiota in childhood obesity

Gut microbiota and therapy for obesity and type 2 diabetes

The gut microbiota in obesity and weight management: microbes as friends or foe?

Cross-Talk Between Gut Microbiota and Adipose Tissues in Obesity and Related Metabolic Diseases

Gut Microbiota, Immunity, and Bile Acid Metabolism: Decoding Metabolic Disease Interactions